“Peter has helped sustain Merck’s commitment to outstanding science and innovation during a period of enormous change for our company and our industry,” said Frazier. “His contributions have positioned us well for future success. Over the past decade, Peter led MRL through an immense transition in pharmaceutical research and development, oversaw important advances in our use of new technologies, began leveraging external innovation and led the creation of an integrated, industry-leading pipeline following our merger with Schering-Plough.”

“I am deeply grateful to the incredibly talented and dedicated people of MRL who have worked with me over the past 12 years on our mission of delivering medicines and vaccines to improve human health around the world,” said Kim. “I am very pleased with Roger’s appointment and confident that he is the right person to lead MRL into the future, and am committed to ensuring a seamless leadership transition for this truly special organization and its great people.”

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts